USFDA guidance for petitioned ANDA [Regulatives / Guidelines]

posted by shahajan baig  – India, 2020-07-20 21:50 (272 d 03:35 ago) – Posting: # 21763
Views: 503

Under the guidance of USFDA "Determining Whether to Submit an ANDA or a 505(b)(2) Application Guidance for Industry" it is mentioned as:

"A petitioned ANDA is a type of ANDA for a drug product that differs from the RLD in its dosage form, route of administration, strength, or active ingredient (in a product with more than one active ingredient) and for which FDA has determined, in response to a petition submitted under section 505(j)(2)(C) of the FD&C Act (suitability petition), that studies are not necessary to establish the safety and effectiveness of the proposed drug product. A petitioned ANDA is generally expected to provide the same therapeutic effect as the listed drug that was relied on as the basis of the suitability petition."

I want to know that how can suitability petition can be filed without establishing the safety and effectiveness of the proposed drug.

Thanks in advance


Baig Shahajan



Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 16 (0 registered, 16 guests [including 4 identified bots]).
Forum time: Monday 01:26 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz